Neuberger Berman Group’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.4K Buy
15,350
+1,400
+10% +$1.71K ﹤0.01% 2149
2025
Q4
$13.7K Buy
+13,950
New +$16.8K ﹤0.01% 2101
2024
Q1
Sell
-10,637
Closed -$39.8K 1864
2023
Q4
$39.8K Buy
+10,637
New +$25.1K ﹤0.01% 1817
2022
Q4
Sell
-376,683
Closed -$8.44M 1818
2022
Q3
$8.44M Sell
376,683
-266
-0.1% -$7.69K 0.01% 776
2022
Q2
$9.34M Buy
376,949
+18,757
+5% +$518K 0.01% 763
2022
Q1
$13.9M Buy
358,192
+5,856
+2% +$227K 0.01% 746
2021
Q4
$20.6M Sell
352,336
-32,851
-9% -$1.86M 0.02% 683
2021
Q3
$22.7M Buy
385,187
+124,894
+48% +$9.8M 0.02% 643
2021
Q2
$22.6M Buy
260,293
+203,610
+359% +$16.4M 0.02% 672
2021
Q1
$4.64M Sell
56,683
-4,317
-7% -$414K ﹤0.01% 969
2020
Q4
$5.55M Hold
61,000
0.01% 888
2020
Q3
$2.44M Buy
61,000
+24,000
+65% +$838K ﹤0.01% 1029
2020
Q2
$1.27M Hold
37,000
﹤0.01% 1091
2020
Q1
$822K Sell
37,000
-53,000
-59% -$1.34M ﹤0.01% 1135
2019
Q4
$1.76M Sell
90,000
-17,400
-16% -$276K ﹤0.01% 1057
2019
Q3
$1.67M Buy
107,400
+11,400
+12% +$219K ﹤0.01% 1051
2019
Q2
$1.95M Buy
96,000
+36,000
+60% +$649K ﹤0.01% 1040
2019
Q1
$1.05M Hold
60,000
﹤0.01% 1108
2018
Q4
$770K Sell
60,000
-60,000
-50% -$837K ﹤0.01% 1167
2018
Q3
$1.96M Buy
120,000
+105,000
+700% +$1.24M ﹤0.01% 1037
2018
Q2
$170K Sell
15,000
-138,250
-90% -$1.52M ﹤0.01% 1662
2018
Q1
$1.5M Sell
153,250
-20,000
-12% -$192K ﹤0.01% 1077
2017
Q4
$1.06M Buy
173,250
+40,250
+30% +$180K ﹤0.01% 1185
2017
Q3
$527K Buy
133,000
+83,300
+168% +$283K ﹤0.01% 1293
2017
Q2
$161K Sell
49,700
-18,900
-28% -$72.4K ﹤0.01% 1549
2017
Q1
$312K Buy
+68,600
New +$251K ﹤0.01% 1412

Other funds holding FATE